Literature DB >> 17108141

Ciz1, a Novel DNA-binding coactivator of the estrogen receptor alpha, confers hypersensitivity to estrogen action.

Petra den Hollander1, Suresh K Rayala, Dawn Coverley, Rakesh Kumar.   

Abstract

The transcriptional activity of the estrogen receptor (ER) is affected by regulatory cofactors, including chromatin-remodeling complexes, coactivators, and corepressors. Coregulators are recruited to target gene promoters through protein-protein interactions with ER and function as linker molecules between the DNA, DNA-binding proteins, and DNA-modifying enzymes. We recently showed that Cip-interacting zinc finger protein 1 (Ciz1) participates in the regulation of the cell cycle in estrogen-stimulated breast cancer cells. Despite the emerging significance of Ciz1 in the biology of breast cancer cells, regulation of endogenous Ciz1 in hormone-responsive cancer cells remains unknown. To shed light on the role of Ciz1 in breast tumorigenesis, we defined the regulation of Ciz1 by the ER pathway and found that Ciz1 is an estrogen-responsive gene. We also discovered that Ciz1 protein, a DNA-binding factor, coregulates ER by enhancing ER transactivation activity by promoting the recruitment of the ER complex to the target gene chromatin. In addition, we found that Ciz1 overexpression confers estrogen hypersensitivity to breast cancer cells and promotes the growth rate, anchorage independency, and tumorigenic properties of breast cancer cells. These findings revealed the inherent role of Ciz1, a novel DNA binding and ER coactivator, in amplifying estrogenic responses and promoting breast cancer tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17108141     DOI: 10.1158/0008-5472.CAN-06-2336

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  Palmitoylation regulates 17β-estradiol-induced estrogen receptor-α degradation and transcriptional activity.

Authors:  Piergiorgio La Rosa; Valeria Pesiri; Guy Leclercq; Maria Marino; Filippo Acconcia
Journal:  Mol Endocrinol       Date:  2012-03-22

2.  Consequences of Cre-mediated deletion of Ciz1 exon 5 in mice.

Authors:  Jianfeng Xiao; Mohammad Moshahid Khan; Satya Vemula; Jun Tian; Mark S LeDoux
Journal:  FEBS Lett       Date:  2018-08-29       Impact factor: 4.124

3.  Motor phenotypes and molecular networks associated with germline deficiency of Ciz1.

Authors:  Jianfeng Xiao; Satya R Vemula; Yi Xue; Mohammad M Khan; Korah P Kuruvilla; Esther M Marquez-Lona; Madison R Cobb; Mark S LeDoux
Journal:  Exp Neurol       Date:  2016-05-07       Impact factor: 5.330

Review 4.  Modulating the expression of Chtop, a versatile regulator of gene-specific transcription and mRNA export.

Authors:  Keiichi Izumikawa; Hideaki Ishikawa; Richard J Simpson; Nobuhiro Takahashi
Journal:  RNA Biol       Date:  2018-05-11       Impact factor: 4.652

5.  Regulation of hormonal therapy resistance by cell cycle machinery.

Authors:  Binoj Chandrasekharan Nair; Ratna K Vadlamudi
Journal:  Gene Ther Mol Biol       Date:  2008-01-01

6.  CIZ1 promoted the growth and migration of gallbladder cancer cells.

Authors:  Dexiang Zhang; Yueqi Wang; Yuedi Dai; Jiwen Wang; Tao Suo; Hongtao Pan; Han Liu; Sheng Shen; Houbao Liu
Journal:  Tumour Biol       Date:  2014-11-28

7.  CIZ1 Expression Is Upregulated in Hemangioma of the Tongue.

Authors:  Yue Wang; Xiaorui Li; Jiahao Zhang; Qiang Liu; Peng Gao; Di Li; Shijie Zhang; Ju Liu
Journal:  Pathol Oncol Res       Date:  2018-11-19       Impact factor: 3.201

8.  Differential detection of alternatively spliced variants of Ciz1 in normal and cancer cells using a custom exon-junction microarray.

Authors:  Faisal A Rahman; Naveed Aziz; Dawn Coverley
Journal:  BMC Cancer       Date:  2010-09-10       Impact factor: 4.430

9.  Variant Ciz1 is a circulating biomarker for early-stage lung cancer.

Authors:  Gillian Higgins; Katherine M Roper; Irene J Watson; Fiona H Blackhall; William N Rom; Harvey I Pass; Justin F X Ainscough; Dawn Coverley
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-16       Impact factor: 11.205

Review 10.  Emerging common molecular pathways for primary dystonia.

Authors:  Mark S Ledoux; William T Dauer; Thomas T Warner
Journal:  Mov Disord       Date:  2013-06-15       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.